Adverse Cutaneous Reactions to Selective Cyclooxygenase 2 Inhibitors: Experience of an Italian Drug-Surveillance Center

Abstract

French

Background:

Selective cyclooxygenase (COX) 2 nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with a general lower incidence of side effects compared with nonselective NSAIDs. Postmarketing information has highlighted the need to reassess the risk evaluation for specific organs, including the skin.

Objective:

A prospective databank to record all cases of adverse cutaneous reactions associated with the use of COX inhibitors was conducted at the Centre for Drug Surveillance of the Dermatology Department of Cagliari University.

Material and Methods:

An intensive surveillance program from November 2000 to October 2004, adopting the World Health Organization Collaborating Centre for Drug Monitoring causality assessment criteria and algorithm.

Results:

Seventeen cases, 4 male and 13 female, were studied. None had previously presented any drug intolerance or allergy. Clinical manifestations were mainly maculopapular exanthema followed by urticaria-angioedema. A severe case of leukocytoclastic vasculitis was also observed. Responsible drugs were celecoxib (13 cases; 76%), rofecoxib (3 cases; 18%), and etoricoxib (1 case; 6%). All cases recovered with drug withdrawal. Causality was probable for all eruptions, except for the fixed drug eruption, for which causality was certain.

Discussion:

Although most cases were associated with celecoxib, the observation of severe eruptions owing to rofecoxib and etoricoxib in this prospective study is consistent with a class effect of COX inhibitors on the skin, which merits further studies to explain the fine underlying mechanisms.

Get full access to this article

View all access options for this article.

References

Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993;186:164–9.

FitzGerald

. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–11.

Shapiro

Knowles

Weber

. Safety of celecoxib in individuals allergic to sulfonamide: A pilot study. Drug Saf 2003;26:187–95.

Picado

. COX-2 specific inhibitors in NSAID-intolerant patients. Int J Immunopathol Pharmacol 2003;16:11–6.

Senna

Bilo

Antonicelli

. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Allerg Immunol 2004;36:215–8.

Knowles

Shapiro

Shean

. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Druf Saf 2001;24:239–42.

Juni

Nartey

Reichenbach

. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004;364:2021–9.

Marques

Milpied

Foulc

. Severe cutaneous drug reactions to celecoxib. Ann Dermatol Venereol 2003;130:1051.

Murr

Bocquet

Lelouet

. Adverse cutaneous reaction to celecoxib: 6 cases. Ann Dermatol Venereol 2003;130:519.

10.

Schneider

Meziani

Chartier

. Fatal allergic vasculitis associated with celecoxib. Lancet 2002;359:852–3.

11.

Report of a WHO meeting. World Health Organ Rep Series 1972;498:1–25.

12.

Verbeiren

Morant

Charlanne

. Celecoxib-induced toxic skin reaction with positive patch test. Ann Dermatol Venereol 2002;129:203–5.

13.

Litt

. Pocketbook of drug eruptions and interactions. New York: The Parthenon Publishing Group; 1999.

14.

Mahajan

Sharma

. COX-2 selective nonsteroidal anti-inflammatory drugs: Current status. J Assoc Physicians India 2005;53:200–4.